Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126789 · ClinicalTrials.gov registry record · Phase 3
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
A Phase 3 study, sponsored by ZARS Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00126789: Clinical Trial Phase 3 study, sponsored by ZARS Pharma.
NCT00126789 is a Phase 3 study that was terminated before completion, run by ZARS Pharma. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126789, a Phase 3 study, was terminated before completion, sponsored by ZARS Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
Primary Outcome
To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain
Interventions
- DRUG Fentanyl Transdermal Matrix Patch ZR-02-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Why NCT00126789 stopped before completion
NCT00126789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Fentanyl Transdermal Matrix Patch ZR-02-01 is the first listed.
NCT00126789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00126789 about?
NCT00126789 is a clinical study titled "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain". The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
What is the current status of trial NCT00126789?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2005-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00126789?
The interventions under investigation include: Fentanyl Transdermal Matrix Patch ZR-02-01 (DRUG).
Who is sponsoring clinical trial NCT00126789?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00126789's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia